Heart failure is a clinical syndrome that may result from different disease states or conditions that injure the myocardium. The activation of circulating neurohormones, particularly aldosterone, may play a pivotal role in left ventricular (LV) remodelling. The Randomized Aldactone Evaluation Study and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival trial have emphasised the clinical importance of aldosterone. This review addresses some of the proposed mechanisms of LV remodelling in heart failure.
Jessup M., Brozena S.Heart failure. N Engl JMed2003; 348: 2007-18.
2.
Struthers ADAldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J1995 ;16(suppl N):103-06.
3.
Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L.Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group . Circulation1990;82:1730-6.
4.
Mornet E., Dupont J.,Vitek A.,White PCCharacterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem1989; 264:20961-7.
5.
Mizuno Y., Yoshimura M., Yasue H. et al. Aldosterone production is activated in failing ventricle in humans. Circulation2001;103:72-7.
6.
Tsutamoto T.,Wada A.,Maeda K. et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol2000;36:838-44.
7.
Young MJ, Clyne CD, Cole TJ, Funder JWCardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab2001;86:5121-6.
8.
Silvestre JS , Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem1998;273:4883-91.
9.
Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H.Cardiac aldosterone production in genetically hypertensive rats. Hypertension2000;36:495-500.
10.
Young MJ, Clyne CD, Cole TJ, Funder JWCardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab2001;86:5121-6.
11.
Satoh M., Nakamura M., Saitoh H. et al.Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond)2002;102:381-6.
12.
Yoshimura M. , Nakamura S., Ito T. et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab2002;87:3936-40.
13.
Xiu JC,Wu P., Xu JP et al. Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J Endocrinol Invest2002;25:463-8.
14.
Hanawa H., Abe S., Hayashi M. et al. Time course of gene expression in rat experimental autoimmune myocarditis. Clin Sci (Lond)2002;103:623-32.
15.
Kayes-Wandover KM, White PCSteroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab2000;85:2519-25.
16.
Silvestre JS , Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem1998;273:4883-91.
17.
Young MJ, Moussa L., Dilley R., Funder JWEarly inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology2003;144:1121-5.
18.
Takeda Y., Miyamori I., Yoneda T. et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab1996;81:2797-800.
19.
White PCAldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab2003;88:2376-83.
20.
Lombes M., Oblin ME, Gasc JM, Baulieu EE, Farman N., Bonvalet JPImmunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res992; 71:503-l0.
21.
Lombes M., Alfaidy N., Eugene E.H.Lessana A., Farman N., Bonvalet JPPrerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation1995;92:175-82.
22.
Bonvalet JPRegulation of sodium transport by steroid hormones . Kidney Int1998;65(suppl):S49-S56.
23.
Mangelsdorf DJ, Thummel C., Beato M. et al. The nuclear receptor superfamily: the second decade. Cell1995;83:835-9.
24.
White PC, Mune T., Agarwal AK11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev1997;18:135-56.
25.
Slight S., Ganjam VK, Nonneman DJ, Weber KTGlucocorticoid metabolism in the cardiac interstitium: 11 beta-hydroxysteroid dehydrogenase activity in cardiac fibroblasts. J Lab Clin Med1993;122:180-7.
26.
Kohler E., Bertschin S., Woodtli T., Resink T., Erne P.Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?J Vasc Res1996;33:315-26.
27.
Stockand JD , Meszaros JGAldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol2003;284:H176-H184.
28.
Fiebeler A. , Schmidt F., Muller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension2001 ;37(2 Part 2):787-93.
29.
Krug AW, Schuster C., Gassner B. et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling . J Biol Chem2002;277:45892-7.
30.
Krug AW, Grossmann C., Schuster C. et al.Aldosterone stimulates epidermal growth factor receptor (EGFR) expression. J Biol Chem2003;278:43060-6.
31.
Qin W., Rudolph AE, Bond BR et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res2003;93:69-76.
32.
Hafezi-Moghadam A., Simoncini T., Yang E. et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med2002;8:473-9.
33.
Beggah AT, Escoubet B., Puttini S. et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes . Proc Natl Acad Sci U S A2002;99:7160-5.
34.
Christ M., Meyer C., Sippel K.,Wehling M.Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun1995;213:123-9.
35.
Sato A., Liu JP, Funder JWAldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro.Endocrinology1997;138:3410-16.
36.
Good DW, George T., Watts BA 3rd.Aldosterone potentiates 1,25-dihydroxyvitamin D3 action in renal thick ascending limb via a nongenomic, ERK-dependent pathway. Am J Physiol Cell Physiol2003;285:C1122-30.
37.
Wehling M., Spes CH, Win N. et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab1998; 83:3517-22.
38.
Ball AM, Sole MJOxidative stress and the pathogenesis of heart failure. Cardiol Clin1998;16(4):665-6ix.
39.
Keith ME, Jeejeebhoy KN, Langer A. et al.A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr2001;73:219-24.
40.
Sole MJ, Jeejeebhoy KNConditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care2000;3:417-24.
Cesselli D. , Jakoniuk I., Barlucchi L. et al. Oxidative stressmediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res2001 ;89:279-86.
43.
Tsutsui H., Ide T., Hayashidani S. et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation2001;104: 134-6.
44.
Haugen EN, Croatt AJ, Nath KAAngiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int2000;58:144-52.
45.
Rajagopalan S., Kurz S., Munzel T. et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone . J Clin Invest1996;97:1916-23.
46.
Wang HD, Pagano PJ, Du Y. et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res1998;82:810-18.
47.
Swei A., Lacy F., DeLano FA, Schmid-Schonbein GWOxidative stress in the Dahl hypertensive rat. Hypertension1997;30:1628-33.
48.
Laursen JB, Rajagopalan S., Galis Z.,Tarpey M., Freeman BA, Harrison DGRole of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation1997; 95:588-93.
49.
Kerr S., Brosnan MJ, McIntyre M., Reid JL, Dominiczak AF, Hamilton CASuperoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension1999 ;33:1353-8.
50.
Ide T., Tsutsui H., Kinugawa S. et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res1999;85:357-63.
51.
Nath R., Kumar D., Li T., Singal PKMetallothioneins, oxidative stress and the cardiovascular system. Toxicology2000; 155:17-26.
52.
Somers MJ, Mavromatis K., Galis ZS, Harrison DGVascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation2000;101:1722-8.
53.
Gryglewski RJ, Palmer RM, Moncada S.Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor . Nature1986;320:454-6.
54.
Schnackenberg CG,Wilcox CSTwo-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha . Hypertension1999;33(1 Pt 2):424-8.
55.
Singal PK, Beamish RE, Dhalla NSPotential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol1983;161:391-401.
56.
Griendling KK, Sorescu D., Lassegue B., Ushio-Fukai M.Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol2000;20: 2175-83.
57.
Virdis A., Neves MF, Amiri F., Viel E.,Touyz RM, Schiffrin ELSpironolactone improves angiotensin-induced vascular changes and oxidative stress.Hypertension2002;40:504-10.
58.
Pu Q., Neves MF, Virdis A., Touyz RM, Schiffrin ELEndothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension2003;42:49-55.
59.
Sun Y., Zhang J., Lu L., Chen SS, Quinn MT, Weber KTAldosterone-induced inflammation in the rat heart: role of oxidative stress . Am J Pathol2002;161:1773-81.
60.
Li JS, Lariviere R., Schiffrin ELEffect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension1994; 24:183-8.
61.
Tostes RC, Touyz RM, He G., Chen X., Schiffrin ELContribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci (Lond)2002;103(suppl 48):25S-30S.
62.
Cambiaggi C. , Mencarelli M., Muscettola M., Grasso G.Gene expression of endothelin-1 (ET-1) and release of mature peptide by activated human neutrophils . Cytokine2001; 14:230-3.
63.
Scholz H., Kramer BK, Hamann M., Gotz KH, Kurtz A.Effects of endothelins on renin secretion from rat kidneys. Acta Physiol Scand1995;155:173-82.
64.
Rossi GP, Sacchetto A., Cesari M., Pessina ACInteractions between endothelin-1 and the renin-angiotensin-aldosterone system . Cardiovasc Res1999;43:300-07.
65.
Keidar S., Hayek T., Kaplan M. et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol2003 ;41:955-63.
66.
Farquharson CA, Struthers ADSpironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation2000;101:594-7.
67.
Williams JS ,Williams GH50th anniversary of aldosterone . J Clin Endocrinol Metab2003;88:2364-72.
68.
Anker SD, Chua TP, Ponikowski P. et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation1997;96: 526-34.
69.
Weber KTAldosterone in congestive heart failure. N Engl J Med2001;345:1689-97.
70.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med1987;316:1429-35.
71.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators . N Engl J Med1991;325:293-302.
72.
MacFadyen RJ , Lee AF, Morton JJ, Pringle SD, Struthers ADHow often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?Heart1999;82:57-61.
73.
McKelvie RS , Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.Circulation1999 ;100:1056-64.
74.
Staessen J. , Lijnen P., Fagard R., Verschueren LJ, Amery A.Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol1981;91:457-65.
75.
Cohn JN,Tognoni G.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001;345:1667-75.
76.
McMurray JJ , Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet2003;362: 767-71.
77.
Pitt B., Zannad F., Remme WJ et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators . N Engl J Med1999;341:709-17.
78.
Brilla CG, Matsubara LS, Weber KTAnti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol1993;25: 563-75.
79.
Brilla CG, Pick R.,Tan LB, Janicki JS,Weber KTRemodeling of the rat right and left ventricles in experimental hypertension . Circ Res1990;67:1355-64.
80.
Brilla CG, Weber KTReactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res1992;26:671-7.
81.
Lacolley P. , Labat C., Pujol A., Delcayre C., Benetos A., Safar M.Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation2002;106:2848-53.
82.
ChunTY,Bloem LJ , Pratt JHAldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology2003;144:1712-17.
83.
Lijnen P., Petrov V.Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol2000;32:865-79.
84.
Fullerton MJ , Funder JWAldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res1994;28:1863-7.
85.
Ullian ME, Walsh LG, Morinelli TAPotentiation of angiotensin II action by corticosteroids in vascular tissue . Cardiovasc Res1996;32:266-73.
86.
Brilla CG, Zhou G., Matsubara L.,Weber KTCollagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol1994;26: 809-20.
87.
Saksela O., Rifkin DBCell-associated plasminogen activation: regulation and physiological functions . Annu Rev Cell Biol1988;4:93-126.
88.
Alexander CM , Werb Z.Proteinases and extracellular matrix remodeling . Curr Opin Cell Biol1989 ;1:974-82.
89.
Eitzman DT, McCoy RD, Zheng X. et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene . J Clin Invest1996;97:232-7.
90.
Ullian ME, Schelling JR, Linas SLAldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension1992;20:67-73.
91.
Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab2000;85:33644.
92.
Rocha R., Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol2002;283:H1802-H1810.
93.
Rocha R., Martin-Berger CL, Yang P., Scherrer R., Delyani J., McMahon E.Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology2002;143:4828-36.
94.
Robert V., Heymes C., Silvestre JS, Sabri A., Swynghedauw B., Delcayre C.Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension1999;33:981-6.
95.
Benitah JP, Vassort G.Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes . Circ Res1999;85:1139-45.
96.
Molkentin JD , Lu JR,Antos CL et al.A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell1998 ;93:215-28.
97.
Takeda Y., Yoneda T., Demura M., Usukura M., Mabuchi H.Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy . Circulation2002;105:677-9.
Neumann S., Huse K., Semrau R. et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension2002;39:756-60.
100.
Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H.Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy . Endocrinology2000;141:1901-04.
101.
Delles C., Schmidt BM, Muller HJ, Oehmer S., Klingbeil AU, Schmieder REFunctional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol2003;91: 297-301.
102.
Wencker D. , Chandra M., Nguyen K. et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest2003;111:1497-504.
103.
Leri A., Claudio PP, Li Q. et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest1998; 101:1326-42.
104.
De Angelis N., Fiordaliso F., Latini R. et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol2002; 34:1655-65.
105.
Ben Rhouma K., Schimchowitsch S., Stoeckel ME, Felix JM, Sakly M.[Implication of type II glucocorticoid receptors in aldosterone induced apoptosis of rat thymocytes] . Arch Physiol Biochem1997;105:216-24.
106.
McCullers DL , Sullivan PG, Scheff SW, Herman JPMifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat. Neuroscience2002;109:219-30.
107.
Sam F., Kerstetter DL, Ooi H. et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens2004; 17:188-93.
108.
Ramires FJ, Mansur A., Coelho O. et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy . Am J Cardiol2000;85:1207-11.
109.
Hallstrom A. , Pratt CM, Greene HL et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol1995;25:1250-7.
110.
Zannad F.Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol1993;71:34A-39A.
111.
Barr CS, Lang CC, Hanson J., Arnott M., Kennedy N., Struthers ADEffects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol1995;76:1259-65.
112.
Weber MA, Purdy RECatecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci1982;30:2009-17.
113.
Zannad F., Alla F., Dousset B., Perez A., Pitt B.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators . Circulation2000;102:2700-06.
114.
Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation2003; 108:1831-8.
115.
Gerstein HC , Mann JF, Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA2001;286:421-6.
116.
Epstein M. , Buckalew V., Altamirano J., Roniker B., Krause S., Kleiman J.Eplerenone Reduces Proteinuria in Type II Diabetes Mellitus: Implications for Aldosterone Involvement in the Pathogenesis of Renal Dysfunction. JACC2002;39(suppl 1): 249A.
117.
Pitt B., Remme W., Zannad F., Neaton J. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med2003;348:1309-21.
Funder JWAldosterone resurgens--letter from EPHESUS. J Clin Endocrinol Metab2003;88:2373-5.
120.
Weinberger MHSalt sensitivity of blood pressure in humans . Hypertension1996;27(3 Pt 2):481-90.
121.
Pratt JH, Rebhun JF, Zhou L. et al. Levels of mineralocorticoids in whites and blacks. Hypertension1999;34:315-19.
122.
Yancy CWHeart failure in blacks: etiologic and epidemiologic differences. Curr Cardiol Rep2001;3:191-7.
123.
Flack JM, Oparil S., Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.JAm Coll Cardiol2003;41:1148-55.
124.
Weinberger MH, Roniker B., Krause SL, Weiss RJEplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.AmJHypertens2002;15:709-16.
125.
Krum H., Nolly H.,Workman D. et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension2002;40:117-23.
126.
Takeda Y., Miyamori I., Yoneda T. et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab1996;81:2797-800.
127.
Hatakeyama H., Miyamori I., Fujita T., Takeda Y., Takeda R., Yamamoto H.Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. JBiol Chem1994;269:24316-20.
128.
Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H., Foecking MF, Gomez-Sanchez EPAldosterone biosynthesis in the rat brain . Endocrinology1997;138:3369-73.
129.
Takeda Y., Miyamori I.,YonedaT. et al. Production of aldosterone in isolated rat blood vessels. Hypertension1995;25:170-3.
130.
Patel PD, Sherman TG, Goldman DJ, Watson SJMolecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol1989 ;3:1877-85.
131.
Pearce P., Funder JWHigh affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol1987;14(11-12):859-66.
132.
TakedaY., Miyamori I., Inaba S. et al.Vascular aldosterone in genetically hypertensive rats. Hypertension1997;29(1 Pt 1): 45-8.
133.
Benetos A. , Lacolley P., Safar MEPrevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol1997;17:1152-6.
134.
Young M., Head G., Funder J.Determinants of cardiac fibrosis in experimental hypermineralocorticoid states . Am J Physiol1995;269(4 Pt 1):E657-E662.
135.
Ikeda U., Kanbe T., Nakayama I., Kawahara Y., Yokoyama M., Shimada K.Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol1995;290:69-73.
136.
Farquharson CA , Struthers ADAldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an 425-31.
137.
Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J1998;19:1371-6.
138.
Blacher J. , Amah G., Girerd X. et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens1997;10(12 Pt 1):1326-34.
139.
White PC, Slutsker L.Haplotype analysis of CYP11B2. Endocr Res1995;21:437-442.
140.
Kupari M., Hautanen A., Lankinen L. et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation1998;97:569-75.
141.
Brand E., Chatelain N., Mulatero P. et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension.Hypertension1998;32:198-204.
142.
Lajemi M., Labat C., Gautier S. et al.Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens2001;19:407-13.
143.
Takai E., Akita H., Kanazawa K. et al. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular volume in patients with dilated cardiomyopathy. Heart2002;88:649-50.
144.
Tiago AD, Badenhorst D., Skudicky D. et al.An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res2002;54:584-9.
145.
Sato A., Funder JWHigh glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology1996;137:4145-53.
146.
Trueblood NA, Xie Z., Communal C. et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res2001 ;88:1080-7.
147.
Campos AH, Zhao Y., Pollman MJ, Gibbons GHDNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res2003;92:111-18.
148.
Gerling IC , Sun Y., Ahokas RA et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype . Am J Physiol Heart Circ Physiol2003;285:H813-H821.
149.
Ahokas RA,Warrington KJ, Gerling IC et al.Aldosteronism and Peripheral Blood Mononuclear Cell Activation. A Neuroendocrine-Immune Interface. Circ Res2003;93:124-35.
